Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action
The Peripheral Vascular Disease Research Chair and Division of Vascular Surgery, Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Purpose: Atherosclerotic disease (AD) is the leading cause of death worldwide and in Saudi Arabia. Intensive risk reduction therapy plays a major role in reducing adverse cardiovascular outcomes in patients with AD. The level of awareness of this important fact amongst physicians (family physicians, general internists, cardiologists and vascular surgeons) in managing these patients in Saudi Arabia is not currently known. This study was conducted to examine the perceptions and knowledge of risk reduction therapy in patients with AD amongst physicians in Saudi Arabia in two clinical presentations; coronary artery disease (CAD) and peripheral artery disease (PAD).
Materials and methods: We conducted a cross-sectional self-administered survey of 897 physicians at different hospitals in four provinces in Saudi Arabia.
Results: The recommended targets of low density lipoprotein-cholesterol (LDL-C), blood glucose, and blood pressure in patients with CAD and PAD were known as 40% and 36%; 70% and 66%; and 32% and 28% of physicians, respectively. The initiation of antiplatelet medications, angiotensin converting enzyme (ACE) inhibitors, statins, and nicotine replacement therapy for smokers in patients with CAD and PAD were recommended by 98% and 97%; 52% and 34%; 61% and 56%; and 50% and 43% of physicians, respectively. Compared to other specialties, cardiologists had the lowest threshold for initiating risk reduction therapy, whereas vascular surgeons had the highest threshold.
Conclusion: The level of physician awareness of atherosclerosis risk reduction therapy across Saudi Arabia has revealed knowledge and action gaps. A call to action to implement effective strategies to encourage health professionals to use risk reduction therapy and increase public awareness is needed.
Keywords: coronary artery disease, peripheral arterial disease, risk reduction, atherosclerosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Gracida M, Romaguera R, Jacobi F, Gómez-Hospital JA, Cequier A
Published Date: 18 September 2015
Fahrni J, Husmann M, Gretener SB, Keo HH
Published Date: 17 August 2015
Ihle-Hansen H, Thommessen B, Fagerland MW, Øksengård AR, Wyller TB, Engedal K, Fure B
Published Date: 9 June 2015
Sertoglu E, Uyanik M
Published Date: 20 December 2013
Kalanuria AA, Nyquist P, Ling G
Published Date: 25 September 2012
Burke RM, Evans JD
Published Date: 29 August 2012
Shuster JE, Bleske BE, Dorsch MP
Published Date: 13 June 2012
Leonetti G, Egan CG
Published Date: 18 May 2012
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases
Published Date: 15 May 2012
Kurtz TW, Kajiya T
Published Date: 28 February 2012